Lifeboat Foundation

https://www.stitcher.com/podcast/ctr-network/aging-greatfull…e/53449222

In Unexpected Futurist, we profile the lesser known futurist side of influential individuals. This episode’s unexpected time-traveler: Benjamin Franklin. Ben Franklin was an inventor, observer, electricity pioneer, and serial experimenter, so it’s not entirely surprising he looked to the future. But it turns out he was looking to the far, far future. In 1780 he wrote a letter to a friend in which he lamented that he was born during the dawn of science.

Follow us on social media:
Twitter / Facebook / Instagram

This film was compiled from audio of a discussion futurist FM-2030 held at the University of California on February 6th, 1994. In this discussion 2030 laid out an overview of his ‘transhuman’ philosophy and held a back and forth with other people present in the discussion. Discussion and debate included items such as the value of researching ‘indefinite lifespan’ technologies directly as opposed to (or in addition to) more traditional approaches, such as researching cures for specific diseases.
The excerpts in this archive file present a sort of thesis of FM 2030’s transhuman ideas.

About FM 2030: FM 2030 was at various points in his life, an Iranian Olympic basketball player, a diplomat, a university teacher, and a corporate consultant. He developed his views on transhumanism in the 1960s and evolved them over the next thirty-something years. He was placed in cryonic suspension July 8th, 2000. For more information about FM 2030, view the GPA Archive File: ‘Introduction to FM 2030′ or visit some of the following links:

Continue reading “FM-2030: Are You Transhuman?” »

Fox 29 — Good Day Philadelphia

http://www.fox29.com/140735577-video

NBC TV 10

Continue reading “Bringing The Dead Back To Life — Reanima Project / Bioquark Inc. Media Coverage” »

Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of novel biologics for complex regeneration and disease reversion, and Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational therapeutic applications of autologous stem cells, have announced that they have received IRB approval for a study focusing on a novel combinatorial approach to clinical intervention in the state of brain death in humans.

This first trial, within the portfolio of Bioquark’s Reanima Project (http://www.reanima.tech) is entitled “Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury” (https://clinicaltrials.gov/ct2/show/NCT02742857?term=bioquark&rank=1), will enroll an initial 20 subjects, and be conducted at Anupam Hospital in Rudrapur, Uttarakhand India.

Continue reading “Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study” »